Literature DB >> 17090762

Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.

Peter E Callegari, Thomas F Schaible, Jerome A Boscia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17090762     DOI： 10.1001/jama.296.18.2202

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Therapy: The risk of herpes zoster: another cost of anti-TNF therapy?

Authors:  Tim Bongartz; Robert Orenstein
Journal:  Nat Rev Rheumatol       Date:  2009-07       Impact factor: 20.543

2.  Honokiol possesses potential anti-inflammatory effects on rheumatoid arthritis and GM-CSF can be a target for its treatment.

Authors:  Xiao-Dong Wang; Ying-Liang Wang; Wen-Feng Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

3.  Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains.

Authors:  I-Ju Chen; Chih-Hung Chuang; Yuan-Chin Hsieh; Yun-Chi Lu; Wen-Wei Lin; Chien-Chiao Huang; Ta-Chun Cheng; Yi-An Cheng; Kai-Wen Cheng; Yeng-Tseng Wang; Fang-Ming Chen; Tian-Lu Cheng; Shey-Cherng Tzou
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

4.  A systematic review of infliximab in the treatment of early rheumatoid arthritis.

Authors:  Sophie Martin Du Pan; Cem Gabay; Axel Finckh
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.